Company intelligence / Profile preview

Hangzhou Guangliang Biomedical

Hangzhou, Zhejiang Sheng (Zhejiang Province), China

Ownership: Private
Development stage: Other

Overview

Hangzhou Guangliang Biomedical is a private Chinese biotech company focused on small molecule drug development for hematological and immune system diseases. Its lead asset, bewintinib, is a JAK inhibitor in Phase 3 clinical trials for polycythemia vera and has also been studied in myelofibrosis[1][2][4][8]. The company appears to have at least one late-stage clinical program but limited public information on broader pipeline or technology platforms.

Therapeutic areas: Hematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

bewintinib

Partnerships

Hangzhou Bangshun Pharmaceutical Co Ltd (clinical trial sponsor/collaborator)

Beyond the preview

Go deeper on Hangzhou Guangliang Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Guangliang Biomedical.